The latest Market Talks covering Equities. Published exclusively on Dow Jones Newswires throughout the day.
0439 GMT - IHH Healthcare is trading at the lower end among regional hospital peers and near historical lows despite an accelerating growth outlook, Macquarie analyst Amanda Foo says in a note. Macquarie estimates Ebitda to grow at an annualized 17% rate in FY26-29, versus 12% in FY22-25. IHH's earnings momentum is improving across Singapore, Malaysia and India. IHH's medical-tourism exposure is also underappreciated, with foreign patients contributing 14.5% of Malaysian revenue in 1H26, Foo says. She maintains an outperform rating and target price of 11.10 ringgit. Shares are up 5.1% at 8.01 ringgit.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.